MiNK Therapeutics Corporate Update and First Quarter 2022 Financial Report
Clinical updates from solid tumor cancers and ARDS with allo-agenT-797 are on track for 2H 2022GMP manufacturing launch in 1H 2022 with target 10,000 doses/yrBCMA-CAR-iNKT and stromal-CAR-iNKT... | May 10, 2022
Source: marketscreener.com